SCHEMBL4335861

SCHEMBL4335861

COCCc1nc2c(N)nc3c(c2n1CCOCCN)CCCC3

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 6/20 0.42
TLR7 Q9NYK1 16/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3872445 0.89 TLR7 (0.39) TLR8TLR7
SCHEMBL4340474 0.89 TLR7 (0.35) TLR8TLR7
SCHEMBL3823104 0.88 TLR7 (0.43) TLR8TLR7
SCHEMBL5105292 0.85 TLR7 (0.37) TLR8TLR7
SCHEMBL483634 0.80 TLR7 (0.44) TLR8TLR7
SCHEMBL31006028 0.80 TLR7 (0.44) TLR8TLR7
SCHEMBL6705491 0.80 SMN1; SMN2 (0.35) TLR8
SCHEMBL7101492 0.80 TLR7 (0.44) TLR7
SCHEMBL1894935 0.79 TLR8 (0.35) TLR8TLR7
SCHEMBL6031144 0.79 TLR7 (0.44) TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612083-B2 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-11-03 US disclosed
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-11 US disclosed
US-7214675-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-08 US disclosed
EP-1341790-B1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2007-02-14 EP disclosed
US-7132429-B2 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-07 US disclosed
US-7115622-B2 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-03 US disclosed
US-7078523-B2 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-07-18 US disclosed
US-7049439-B2 Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents 3M INNOVATIVE PROPERTIES CO. (US) 2006-05-23 US disclosed
EP-1343784-B1 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. 3M INNOVATIVE PROPERTIES CO (US) 2006-03-08 EP disclosed
US-20050234088-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2005-10-20 US disclosed
US-6660735-B2 Inducing cytokine biosynthesis; viral diseases, neoplastic disorders 3M INNOVATIVE PROPERTIES COMPANY 2003-12-09 US disclosed
US-6656938-B2 Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-12-02 US disclosed
US-20030187016-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
EP-1343784-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M Innovative Properties Company (US) 2003-09-17 EP disclosed
US-20030158192-A1 Urea substituted imidazoquinoline ethers 3M INNOVATIVE PROPERTIES COMPANY 2003-08-21 US disclosed
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines UBS AG, STAMFORD BRANCH 2003-07-24 US disclosed
US-20030130518-A1 Urea substituted imidazoquinoline ethers COLEY PHARMACEUTICAL GROUP, INC. 2003-07-10 US disclosed
US-20030096835-A1 Amido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-19 US disclosed
WO-2002046191-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187016-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR8 51/4885TLR7 14/4885
US-20080306252-A1 SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES IFNG, IRF3, IL2 TLR8 50/4885TLR7 24/4885
US-20030158192-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR8 273/4885TLR7 84/4885
US-20030139441-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 TLR8 50/4885TLR7 24/4885
US-20050234088-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR8 257/4885TLR7 74/4885
US-20030130518-A1 Urea substituted imidazoquinoline ethers IRF3, EIF2AK2, IFNG TLR8 273/4885TLR7 84/4885
US-20030096835-A1 Amido ether substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR8 51/4885TLR7 14/4885
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 TLR8 50/4885TLR7 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.